Regenxbio (RGNX) expects its balance in cash, cash equivalents and marketable securities of $314.1M as of December 31, 2023 to fund its operations into the second half of 2025. This cash runway guidance is based on the Company’s current operational plans and excludes the impact of any payments that may be received from AbbVie (ABBV) upon the achievement of development or commercial milestones under our ABBV-RGX-314 collaboration.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RGNX:
